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Abstract
AIM: To describe the establishment of a Danish 
inflammatory bowel diseases (IBD) twin cohort with 
focus on concordance of treatment and inflammatory 
markers.
METHODS: We identified MZ twins, likely to be dis-
cordant or concordant for IBD, by merging information 
from the Danish Twin Register and the National Patient 
Register. The twins were asked to provide biological 
samples, questionnaires, and data access to patient 
files and public registries. Biological samples were 
collected via  a mobile laboratory, which allowed for 
immediate centrifugation, fractionation, and storage 
of samples. The mean time from collection of samples 
to storage in the -80 ℃ mobile freezer was less than 
one hour. The diagnoses where validated using the 
Copenhagen diagnostic criteria.
RESULTS: We identified 159 MZ IBD twin pairs, 
in a total of 62 (39%) pairs both twins agreed to 
participate. Of the supposed 62 IBD pairs, the IBD 
diagnosis could be confirmed in 54 pairs. The cohort 
included 10 concordant pairs, whereof some were 
discordant for either treatment or surgery. The 10 
concordant pairs, where both pairs suffered from IBD, 
included eight CD/CD pairs, one UC/UC pair and one 
UC/IBDU pair. The discordant pairs comprised 31 UC, 
5 IBDU (IBD unclassified), and 8 CD discordant pairs. 
In the co-twins not affected by IBD, calprotectin was 
above 100 µg/g in 2 participants, and above 50 µg/g in 
a further 5 participants.
CONCLUSION: The presented IBD twin cohorts are 
an excellent resource for bioinformatics studies with 
proper adjustment for disease-associated exposures 
including medication and inflammatory activity in the 
co-twins. 
Key words: Digestive system diseases; Inflammatory 
bowel diseases; Crohn’s disease; Ulcerative colitis; 
Epidemiologic studies; Twins; Biobank
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Using co-twin study designs to segregate 
genetic and environmental factors in inflammatory 
bowel diseases (IBD) holds promise for future discovery, 
considering subclinical disease in the co-twins. However, 
as MZ IBD discordant twins are rarely seen this often-
mean insufficient power for planned analyses. Hence, 
collaboration between IBD twin resources is crucial. 
Moller FT, Knudsen L, Harbord M, Satsangi J, Gordon H, 
Christiansen L, Christensen K, Jess T, Andersen V. Danish cohort 
of monozygotic inflammatory bowel disease twins: Clinical 
characteristics and inflammatory activity. World J Gastroenterol 
2016; 22(21): 5050­5059  Available from: URL: http://www.
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org/10.3748/wjg.v22.i21.5050
INTRODUCTION
The inflammatory bowel diseases (IBD), Crohn’s 
disease (CD) and ulcerative colitis (UC), affect a large 
number of Europeans[1,2]. Despite the introduction of 
new treatments, CD and UC remain chronic conditions 
with severe disease morbidity, often complicated by 
surgery and frequent admissions to hospital[1,3]. 
Although studies of the genome have found 200 loci 
associated with IBD, the variation in the IBD phenotype 
explained by these finding is still below 25%-30%[4,5] 
suggesting a role of environmental factors in IBD 
pathogenesis. Several studies indicate environmental 
impact on IBD pathogenesis including; exposure to 
pathogens[6], disease associated dysbiosis[7], metabolic 
disequilibrium[8], or epigenetic modifications[9]. More 
comprehensive studies, addressing these and other 
potential causes of IBD, could provide invaluable 
new insight into the pathogenesis of IBD[10], though 
studies using unrelated individuals would require large 
populations to overcome genetic variation between 
unrelated subjects[11]. 
Monozygotic (MZ) twins share common genotypes 
and epigenetic profiles at conception[12]. While some 
epigenetic differences arise during the lifetime of MZ 
twins[13], the inter-individual variation in relation to e.g., 
the epigenome and the gut microbiome remain lower 
between twin pairs than between unrelated persons[14]. 
Consequently, comprehensive studies of the exposome 
using IBD discordant MZ twin study designs could 
prove a powerful tool to assess the combined effects 
of environmental and endogenous factors, and identify 
targets for treatment and prevention[15]. 
A major challenge in such discordant twin pair 
studies is that quiescent or subclinical disease may 
blur the boundaries between cases and their co-twin 
controls[16,17]. Another major challenge is that IBD 
discordant twin pairs are also treatment discordant, 
hence observed differences might derive from diffe-
rential medication rather than disease discordance. 
Given enough power, studies using concordant twin 
pairs in addition to discordant twin pairs could allow 
researchers to adjust for disease-associated exposures 
such as medication, as both twins have IBD but may 
be discordant for some of the applied treatments. 
Further, calprotectin correlates with intestinal inflam-
mation[18-20], and could reflect quiescent or subclinical 
disease in the unaffected co-twins.
We describe the establishment of a Danish IBD 
twin cohort including sampling of biological material, 
and illustrate the importance of treatment discordance 
and measurement of inflammatory markers for future 
bioinformatics studies using IBD affected twins.
MATERIALS AND METHODS
We identified MZ twins, likely to be discordant or concor-
dant for IBD, by merging information from the Danish 
Twin Register and the National Patient Register[21,22].
Danish twin register
The Danish Twin Register enabled identification of MZ 
twins living in Denmark at the time of inclusion, with 
assessment of zygosity correct in 96% of cases[23]. The 
Register contains 72% of all twin pairs born between 
1931-1968, with complete ascertainment of all live 
born twins since 1968[21]. 
National patient register
The National Patient Register is a nationwide register of 
all hospital discharge diagnoses, including surgical and 
other procedures recorded in Danish hospitals since 
1977[22]. The Register provides outpatient data from 
1994 and surgical procedures since 1996. Diagnoses 
of UC and CD were identified using the international 
classification of diseases (ICD) 8th and 10th revision 
codes for CD (563.00-563.09 and K50) and UC (563.19, 
569.04 and K51).
The diagnosis of IBD has previously been found 
to be accurate in over 90% of IBD cases in the na-
tional patient register, using a pathology register as 
reference[24].
Cohort recruitment
Merging the Danish Twin Register and the National 
Patient Register, identified 159 MZ twin pairs in which 
at least one twin had a diagnosis of either CD or UC 
according to the National Patient Register as of May 
1st 2013. Of these, 113 index twins (the first twin to 
contract IBD according to the register) responded to 
the invitational letter of whom 42 twins declined to 
participate. Of the 71 positive index twin responders, 
nine co-twins did not wish to participate, leaving 62 
pairs for inclusion, Figure 1.
Data collection 
The participants filled out a questionnaire including 
age, sex, smoking status, medication, dietary patterns 
including a food frequency questionnaire, a 48-h 
dietary recall, time of last meal or exercise, travel 
history, and pregnancies and disease activity at time of 
sampling, either Harvey Bradshaw Index (CD) (33) or 
Simple Clinical Colitis Index (UC) (34).
Data collected from the patient record included 
disease staging using the Montreal classification (32), 
any IBD complications, extra intestinal manifestations, 
and gastrointestinal operations as well as prior IBD 
medication.
The register diagnosis of CD, UC or IBDU, was 
validated by hospital records and pathology descrip-
tions using the Copenhagen criteria[25]: Copenhagen 
Diagnostic Criteria for CD (at least two of the criteria 
present)[26,27]: (1) History of abdominal pain, weight 
loss and/or diarrhoea for more than three months; 
(2) Characteristic endoscopic findings of ulceration 
(aphthous lesions, snail track ulceration) or cobble 
stoning or radiological features of stricture or cobble 
stoning; (3) Histopathology consistent with Crohn’s 
disease (epitheloid granuloma of Langerhans type 
or transmural discontinuous focal or patchy inflam-
mation); and (4) Fistula and/or abscess in relation to 
affected bowel segments.
Copenhagen diagnostic criteria for UC (all three of 
the criteria present)[26,28]: (1) History of diarrhoea and/
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159 likely MZ IBD pairs as of 2013-01-05
145 discordant pairs and 14 concordant pairs
113 index twins responded to the invitational letter 
71 index twins accepted to participate
9 co-twins did not respond or rejected to participate
62 twin pairs was included in the study
IBD according to treating physician
n  = 54 pairs
Copenhagen criteria 
not fulfilled
n  = 11 pairs
Copenhagen criteria 
fulfilled 
n  = 43 pairs
IBD unlikely
n  = 8 pairs 
Natonal Patient Register 
Diagnosis of either CD or 
UC
Danish Twin Register
All MZ twins alive and aged 
above 18
Figure 1  Collection of twin pairs. IBD: Inflammatory bowel diseases; CD: 
Crohn’s disease; UC: Ulcerative colitis.
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conditions, see supplementary materials Table 1[30,31]. 
Faecal specimens were sampled by participants up until 
48 h before the visit and stored in their own freezer at 
-20 ℃[32]. Samples were then transferred to a -80 ℃ 
freezer at the visit, under which conditions faecal 
samples have been found to be stable in composition[33]. 
Oral samples were collected with a cytobrush (Cytotak™ 
Transwab® Labelled Tube MW148) from the dorsum 
of the tongue, suspended in a buffer medium, and 
immediately frozen at -80 ℃. Paraffin was used to 
collect sputum samples that were either suspended in 
RNA later or frozen directly at -80 ℃. One researcher 
conducted the collection of all samples. All samples 
were analysed using standard methods centrally to 
avoid sampling variation between different centers.
The mean time from collection of samples to 
storage in the -80 ℃ mobile freezer was less than one 
hour, except for blood samples, which were 60 min 
and 15 s please see Supplementary materials Table 
2. Records where kept to ensure identification of any 
deviations from protocol in future analysis.
Statistical analysis
The study included only basic descriptive statistics 
using R version 3.2.0. In order to ensure confiden-
tiality, no grouping of the twins below five pairs was 
presented. The statistical methods of this study 
were reviewed by statistician Mikael Andersson from 
department of epidemiology at Statens Serum Institut.
RESULTS
Study cohort
Out of 62 MZ twin pairs, after scrutinizing patient 
records, register data, and questionnaires, we found 
the index case of eight pairs unlikely to have IBD. 
or rectal bleeding and pus for more than one week 
or repeated episodes; (2) characteristic endoscopic 
findings of continuous ulceration, vulnerability or 
granulated mucosa; and (3) histopathology consistent 
with ulcerative colitis (neutrophils within epithelial 
structures, cryptitis, crypt distortion, crypt abscesses).
Inter-observer variation has previously been found 
with regards to the Montreal classification[29]. To avoid 
potential inter-observer variation one researcher 
validated the diagnoses and assessed the Montreal 
classification (FTM). Furthermore, to improve validity 
of diagnoses and phenotypes, complicated cases were 
reviewed by a gastroenterological specialist and senior 
physician (VAN). In daily clinical practice, the diagnosis 
may remain difficult; therefore, we included cases, 
which were perceived to have IBD by the treating 
physician although not fulfilling the Copenhagen 
criteria as IBD cases according to available information 
from the files. Cases where the diagnosis of IBD 
was unlikely were designated “Gastrointestinal (GI) 
symptoms not IBD” for future reference.
Biological samples
Due to the geographical challenges in sampling a 
nationwide cohort, a mobile lab was set up using a 
camper previously fitted for a similar purpose. The 
camper was equipped with a small lab bench, heating, 
refrigeration, -20 ℃ freezer, a mobile -80 ℃ freezer, as 
well as a swinging bucket centrifuge.
The mobile lab setup allowed researchers to visit 
the twins in their home or another private location. The 
samples were collected adhering to the Sample PRE-
analytical Code (SPREC) and Biospecimen Reporting 
for Improved Study Quality (BRISQ) guidelines, 
logging primary container, pre- and post-centrifugation 
conditions, centrifugation parameters and storage 
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Table 1  Clinical characteristics  n  (%)
Pair type Discordant twin pairs Concordant twin pairs
Status Co-twin CD IBDU UC non-IBD GI symptoms IBD co-twin IBD index twin
n 52 8 5 31 8 10 10
Males/Females 23/29 2/6 1/4 16/15 4/4 4/6 4/6
Age (yr) 50(26-78) 47 (26-67) 57 (34-77) 49 (32-70) 55 (27-78) 49 (28-68) 49 (28-68)
Age at onset 32 (21-47) 43 (23-73) 35 (20-59) 38 (23-62) 21 (14-29) 23 (11-34)
Age at diagnosis 34 (25-46) 41 (29-72) 34 (17-66) 48 (18-72) 24 (11-37) 31 (21-47)
CPH criteria fulfilled 6 (75) 4 (80) 24 (77) 0 (0)   8 (80)   9 (90)
Disease location
   L1 ileal   2 (25)   2 (40)   3 (30)   2 (20)
   L2 colonic   3 (38) 0 (0)   1 (10)   1 (10)
   L3 ileocolonic 0 (0) 0 (0)   4 (40)   4 (40)
   L4 isolated upper disease 0 (0) 0 (0) 0 (0)   1 (10)
   B1 non stricturing non penetrating   4 (50)   2 (40)   3 (30)   1 (10)
   B2 stricturing   2 (25) 0 (0)   4 (40)   5 (50)
   B3 penetrating 0 (0) 0 (0)   3 (30)   2 (20)
   P perianal disease   1 (13) 0 (0)   2 (20) 0 (0)
   Proctitis   1 (20)   6 (19)
   Left sided 0 (0)   9 (29)
   Extensive   1 (20) 10 (32)
n denotes the number of participants with the phenotype described in status. IBD: Inflammatory bowel diseases; CD: Crohn’s disease; UC: Ulcerative colitis.
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The 8 cases were afflicted by the following diagnoses: 
lymphocytic colitis, irritable bowel syndrome, Clo­
stridium Difficile infection, ischemic bowel changes and 
abscesses without pathologic CD features and grouped 
as GI symptoms not IBD. At least one twin suffered 
from IBD in all remaining 54 pairs according to patient 
records before verification of diagnostic criteria. Forty-
four were discordant for IBD, of whom 24 out of 31 UC 
pairs, four out of five IBDU pairs, and six out of eight 
CD pairs fulfilled the Copenhagen diagnostic criteria. Of 
the 10 concordant pairs, there were eight CD/CD pairs, 
one UC/UC pair, and one UC/IBDU pair, where all but 
one CD index twin fulfilled the Copenhagen criteria. 
Both verified and suspected cases were included in the 
cohort, to reflect clinical practice.
Age at diagnosis 
The mean age at diagnosis was lower in the CD 
concordant than CD discordant pairs (24.75 years vs 
31.75 years). The timespan between the diagnosis 
of an index twin and the IBD co-twin was 6 years on 
average, ranging from 94 d to 14 years. The mean 
disease duration at sampling was 15 years on average, 
ranging from 295 d to 37 years.
Clinical characteristics, complications, medication and 
smoking
Table 1 shows clinical characteristics of the discordant 
twin pairs. Nine extra intestinal manifestations were 
present among co-twins, most often arthropathy. 
Table 2 shows complications, medication and smoking. 
Though numbers are small, 25% of CD index twins 
and 63% of CD co-twins received surgery after their 
IBD diagnosis. Conversely, 50% received azathioprine 
among the CD index twins vs 13% among the CD co-
twins.
Assessment of inflammatory activity in concordant and 
discordant twin pairs 
Figure 2A shows inflammatory activity in discordant 
co-twin pairs as measured by calprotectin, at the 
time of sample collection. There was evidence of gut 
inflammation in the apparently non-affected co-twin, 
with faecal calprotectin > 100 µg/g in two individuals 
and > 50 µg/g in a further five (Figure 2A). In two 
of the index twins whose IBD diagnosis could not be 
verified, faecal calprotectin was > 100 µg/g. Values 
of patient reported disease scores were also slightly 
increased though slightly less pronounced (Figure 2B 
and C).
DISCUSSION
We have established a nationwide cohort of 62 affected 
or suspected IBD monozygotic twin pairs, which allow 
assessment of a range of disease- and treatment- 
associated and phenotypical traits amongst both 
discordant and concordant MZ IBD twins. Validation 
of the CD, UC, and IBDU diagnoses resulted in 8 pairs 
where the diagnosis was unlikely, and 11 pairs where 
the diagnosis was likely, but the clinical information 
was too sparse to validate this. Therefore, 43 twin 
pairs fulfilled the Copenhagen diagnostic criteria. The 
cohort included 10 concordant pairs, and several of 
these IBD concordant pairs were discordant for either 
treatment or surgery. The 44 IBD discordant pairs 
comprised 31 UC pairs, five IBDU pairs, and eight CD 
pairs. Inflammatory activity was above the normal 
range in 7 of the co-twins not affected by IBD, with 
calprotectin above 100 µg/g in two co-twin pairs and 
above 50 µg/g in a further five pairs.
The strength of the presented twin cohort lies in 
the wide range of data collected, from questionnaire 
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Table 2  Complications, medication and smoking  n  (%)
Pair type Discordant twin pairs Concordant twin pairs
Status Co-twin CD IBDU UC non-IBD GI symptoms IBD co-twin IBD index twin
n 52 8 5 31 8 10 10
Complications
   GI complications1 3 (6) 2 (25) 1 (20) 2 (6) 0 (0)   4 (40)   5 (50)
   Extra intestinal manifestations2   5 (10) 3 (38) 2 (40) 12 (39)   2 (25)   2 (20)   6 (60)
   Ever surgery 0 (0) 2 (25) 1 (20) 12 (39)   2 (25)   7 (70)   5 (50)
   Colectomy 0 (0) 1 (13) 1 (20)   7 (23) 0 (0) 0 (0) 0 (0)
Medication
   Ever TNF-inhibitor 0 (0) 2 (25) 1 (20)   4 (13) 0 (0)   1 (10)   1 (10)
   Ever glucocorticoids 0 (0) 3 (38) 4 (80) 17 (55)   2 (25)   6 (60)   6 (60)
   Ever other immunosupressor3 0 (0) 4 (50) 2 (40)   6 (19) 0 (0)   2 (20)   5 (50)
   Ever 5-ASA 1 (2) 5 (63) 4 (80) 22 (71)   1 (13)   5 (50)   6 (60)
Smoking
   Never smoker 28 (54) 6 (75) 2 (40) 21 (68)   5 (63)   3 (30)   2 (20)
   Current smoker 10 (19) 1 (13) 1 (20) 2 (6)   2 (25)   3 (30)   7 (70)
   Former smoker 13 (25) 1 (13) 2 (40)   7 (23)   1 (13)   4 (40)   1 (10)
1Fistula, adherences, strictures, toxic megacolon, abscess, perforation, colorectal cancer; 2Hepatitis, primary sclerosing cholangitis, autoimmune pancreatitis, 
uveitis, erythema nodosum, pyoderma gangrenosum, arthritis, aphthous ulcers; 3Methotrexate, azathioprine, and cyclosporine;. n denotes the number of 
participants with the phenotype described in status. IBD: Inflammatory bowel diseases; CD: Crohn’s disease; UC: Ulcerative colitis.
Moller FT et al . A Danish cohort of monozygotic IBD twins
data, patient file and public register data, to multiple 
biological samples. Our mobile laboratory enabled 
uniform collection of biological material with few 
deviations from existing guidelines regarding sample 
collection, storage, and handling. The average time 
from sampling to storage at -80 ℃ was 1 h or less for 
all samples. Our uniform sample collection method 
using a mobile laboratory reduced aberrant data 
handling normally affecting nationwide multicentre 
studies, and allowed for a single-site analysis of 
disease activity data. A drawback of this approach 
is that more advanced laboratory handling, like cell 
separation and preserving viable cells, was not perfor-
med. Instead, the study used CPT tubes, a commercial 
cell preservative, and gradual freezing of cells using a 
“mister frosty”, which has previously been shown to 
preserve viable cells and cell integrity[34]. 
While the collection of biological material in this study 
is more uniform than previous twin studies[14,35-40], we 
were unable to perform invasive manoeuvres such as 
endoscopy with our mobile setup. Though we expect 
to achieve access to some biopsy material taken from 
routine endoscopies, a large proportion of the healthy 
twins had not recently undergone endoscopy, thus 
limiting opportunities for comparison. Our assessment 
of clinical characteristics and IBD medication use 
aggregated data from patient files and questionnaire 
data. Consequently, treatment not documented by 
hospital-based physicians or recalled by patients may 
remain unaccounted for, but this potential bias should 
be similar between concordant and discordant pairs.
Our inclusion rate was lower than expected at 62 
pairs out of the contacted 159, perhaps due to the 
extent of collected samples, and the need for including 
both twins. Indeed, some selection bias favouring 
the inclusion of concordant pairs over discordant 
pairs could not be ruled out, based on the proportion 
of concordant pairs invited to the proportion of 
concordant pairs accepting to participate. 
The IBD twins were identified using nationwide 
registers, reducing bias often bestowed upon twin 
studies relying on advertising for recruitment. Given 
sufficient power, concordant pairs may play a crucial 
role in discerning the effects of disease-associated 
traits, such as medical therapy, from the effects of IBD, 
e.g., on the methylome or metagenome. In addition, 
though we did not have the power to test this formally, 
the mean age at diagnosis seemed lower in the CD 
concordant pairs at 25 years vs 32 years among CD 
discordant pairs. Results from previous twin studies 
are conflicting on this point[41-43]. If indeed such a 
difference exists, one possible explanation might be 
that concordant pairs carry a larger genetic liability to 
disease, with a lower threshold for disease throughout 
life, increasing the risk of both twins contracting IBD, 
resulting in twin concordance. A previous Swedish 
twin study found the total allele frequency of Nod/
Card mutations to be 4.4 times higher among 
concordant twin pairs compared to discordant twin pairs 
contributing to, but not explaining concordance[41].
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Phenotypical characteristics differentiate CD and 
UC from each other and from other conditions such as 
IBS, microscopic colitis and infections. A combination of 
clinical evaluation, endoscopic, histological, radiological, 
and/or bio-chemical investigations provides the 
diagnostic foundation for CD and UC[44,45]. The correct 
classification of twin discordance is paramount. Of 
note, classification is not only dependent on the 
correct diagnosis but also on time interval following the 
diagnosis of the index twin, with the risk of contracting 
IBD declining with time for the co-twin. Although the 
maximum time-span between concordant pairs in 
this cohort was below the mean disease duration of 
15 years in the present cohort, final verification of 
twin discordance can only be assessed at the end of 
the lifespan of both twins. Methods do however exist 
that take time to event into account[46]. While future 
disease may not be a problem in a discordant twin 
study design, this is only true if the exposures causing 
this disease are not already present. Quiescent and 
subclinical disease may complicate the distinction 
between cases and their co-twin controls. Indeed, a 
newly published study indicates the presence of latent 
or emerging disease in family members of affected IBD 
cases[16]. In addition, family members of affected IBD 
cases have increased calprotectin levels as compared 
to the background population[17]. Though a normal 
calprotectin level does not exclude IBD, due to the 
dynamic nature of this condition, and a low level in well 
treated IBD patients, calprotectin levels correlate with 
intestinal inflammation[18-20], and could thus reflect an 
increased liability to IBD in familial members of IBD-
affected cases[47,48]. One[48] twin study published in 
the past 10 years has reported on increased levels of 
intestinal inflammatory activity biomarkers such as 
calprotectin among the unaffected co-twins, while the 
majority of previous twin studies have not[14,35-40,49]. 
We found two co-twins with no history of IBD with 
calprotectin values exceeding 100 µg/g, and a further 
5 with values above the normal range. This may be 
important, as increased calprotectin may reflect that 
many of the exposures leading to disease may already 
be present in a co-twin, if subclinical disease is not 
already present. As a result, inter-individual differences 
with impact on disease pathogenesis within pairs may 
be harder to assess, suggesting that calprotectin levels 
should be considered in analysis.
Disease discordant IBD twins remain rare and 
precious to research[14,35-40,49]. Though providing a 
powerful model for research, this will often mean insuffi-
cient power for planned analyses. Hence, collaboration 
between twin resources is crucial. Collaboration with 
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Figure 3  Figure shows how the collected twin data may be used in different downstream analyses. The figure illustrates the initial genetic concordance 
in liability, the progressive discordance for disease liability due to heterogeneous exposures, and the possible future concordance for IBD, but not necessarily for 
treatment. IBD: Inflammatory bowel diseases.
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the Nixon Twin and Multiplex (TAM) United Kingdom 
IBD cohort, analysing epigenetic data within similar 
biological material, has already been established[50]. 
Thus, both the Danish and the British IBD twin cohorts 
will include a range of clinical, epidemiological and 
biological data enabling researchers to study a cross 
section of the IBD exposome (Figure 3).
The present cohort demonstrates the importance 
of assessing inflammatory biomarkers reflecting 
subclinical inflammatory activity among otherwise 
healthy co-twins in discordant twin studies. The 
present cohort will be part of international collabo-
rations, thereby increasing the power to detect disease-
associated factors, and allow sufficient concordant 
twins to be included in studies to adjust for treatment 
effects. Hypotheses that may be tested include whether 
epigenetic differences controlling IBD loci previously 
identified in GWAS studies exists within the twin 
pairs. Other approaches may include rodent models 
where rodent responses to biological material from 
discordant pairs may differ. Consequently, analysis of 
a range of data from cohorts of monozygotic IBD pairs 
using bioinformatic methods such as metagenomics, 
metabolomics, proteomic and epigenetics could provide 
new insight into the role of the exposome in IBD 
pathogenesis.
COMMENTS
Background
Although studies of the genome have found 200 loci associated with 
inflammatory bowel diseases (IBD), the variation in the IBD phenotype explained 
by these finding is still below 25%-30%, suggesting a role of environmental 
factors in IBD pathogenesis. Several studies indicate environmental impact 
on IBD pathogenesis, including exposure to pathogens, disease-associated 
dysbiosis, metabolic disequilibrium, or epigenetic modifications. Comprehensive 
studies of the exposome using IBD discordant MZ twin co-twin study designs 
could prove a powerful tool to assess the combined effects of environmental 
and endogenous factors, and identify targets for treatment and prevention. 
Research frontiers
Historically twin studies have been used to calculate the heritability of complex 
traits and diseases. The co-twin control design constitutes an excellent model 
to investigate environmental factors associated with disease due to the genetic 
match between monozygotic twins. To date only a few studies have applied 
this method using bioinformatics methods in IBD. Most prominent is the work 
of Jonas Halvforsen and his group in Orebro Sweden that identified differential 
microbial stool patterns between IBD discordant twin pairs, underlining the 
potential of this methodology.
Innovations and breakthroughs
Co-twin control designs may result in complexity reduction, thus increasing 
power to identify microbial or epigenetic patterns associated with IBD and the 
interplay between these complex traits. Such studies necessitate cohorts as 
the one described in this study designed for downstream bioinformatics studies, 
and special emphasis was on pre-analytical sample handling.
Applications
The present cohort demonstrates the importance of assessing inflammatory 
biomarkers reflecting subclinical inflammatory activity among otherwise healthy 
co-twins in discordant twin studies. Using co-twin study designs to investigate 
environmental determinants of disease holds promise for future discovery. 
However, as MZ IBD discordant twins are rare this often means insufficient 
statistical power. Hence, collaboration between twin resources is crucial. 
Through international collaborations analysis of a range of data from cohorts 
of monozygotic IBD pairs using bioinformatic methods such as metagenomics, 
metabolomics, proteomics and epigenetics could provide new insight into the 
role of the exposome in IBD pathogenesis.
Terminology
Concordant twin pairs: twin pairs where both twins are affected by disease or 
trait. Discordant twin pairs: twin pairs where only one twin is affected by disease 
or trait. According to Wild (2005), the exposome encompasses all human 
environmental exposures from conception onwards.
Peer-review
As the authors realize, the real strength of this cohort is in the future 
translational studies, primarily as it relates to epigenetics. While they very briefly 
and superficially discuss these plans in the last paragraph of the conclusion, 
expanding on future plans for hypothesis-driven translational research would 
further strengthen the manuscript. Otherwise, this is a nice introduction to a 
novel cohort that hopes to generate fascinating future work.
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